Clinical trials: Total Body Irradiation, active
Hematological Malignancy
HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib
Now haplo stem cell transplant using bone marrow or peripheral blood is becoming more feasible with better regimens to prevent graft versus host disease (GVHD) like post transplant cyclophosphamide , tacrolimus, mycophenolate .
- Trial name
- NCT03850366
- Testing
- Bortezomib
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Henry Ford Health System
Acute Leukemia, Acute Lymphoblastic Lymphoma
Standard-of-Care Reduced-Intensity Conditioning (RIC) With 200 Versus 400 cGy of Total Body Irradiation (TBI) in Patients With Acute Leukemia Undergoing First Allogeneic Blood or Marrow Transplantation (BMT)
This is a randomized phase II trial of standard-of-care reduced-intensity conditioning (RIC) with 200 versus 400 cGy of total body irradiation (TBI) in patients with acute leukemia undergoing first allogeneic blood or marrow…
- Trial name
- NCT06803745
- Testing
- 200 cGy or 400 cGy total body irradiation (TBI)
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Hematologic Malignancies
Post-Transplant Cyclophosphamide in Patients Aged >/= 65 Years Undergoing Haploidentical Transplant
The purpose of this phase 1 study is to determine the optimal dose of the immune suppressive drug, cyclophosphamide, following standard allogeneic stem cell transplant in patients aged >/= 65 years with hematologic malignancies.
- Trial name
- GeriBMT (NCT05849207)
- Testing
- Cyclophosphamide
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Ronald Paquette
B-cell Acute Lymphoblastic Leukemia
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
This study will evaluate the use of non- TBI (total body irradiation) conditioning for B-ALL patients with low risk of relapse as defined by absence of NGS-MRD (next generation sequencing minimal residual disease) before…
- Trial name
- NCT03509961
- Testing
- NGS-MRD, Myeloablative allogeneic HCT with a non-TBI conditioning regimen
- Where
- 24 sites in United States
- Volunteers
- 95 people
- Sponsor
- Pediatric Transplantation & Cellular Therapy Consortium
T-Cell Lymphocytic Leukemia, ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
BuCy Vs. TBICy for Allo-HSCT in T-ALL Patients
T-cell acute lymphoblastic leukemia (T-ALL), a hematological malignant neoplasm of immature T cells, accounting for a morbidity of 10-15% among pediatric and 20-25% among adult patients of ALL.
- Conditions
- T-Cell Lymphocytic Leukemia, ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Total Body Irradiation, Chemotherapy
- Trial name
- NCT06673459
- Testing
- TBICy, BuCy
- Where
- China
- Volunteers
- 430 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Acute Myeloid Leukemia in Remission, Adult Acute Lymphoblastic Leukemia in Complete Remission
Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
This phase Ib/2 trial studies how well chemotherapy, total body irradiation, and post-transplant cyclophosphamide work in reducing rates of graft versus host disease in patients with hematologic malignancies undergoing a donor…
- Conditions
- Acute Myeloid Leukemia in Remission, Adult Acute Lymphoblastic Leukemia in Complete Remission, Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission, Chronic Myelomonocytic Leukemia in Remission
- Trial name
- NCT03192397
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Roswell Park Cancer Institute
Acute Leukemia, Acute Lymphoblastic Leukemia
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
This phase II trial studies how well a donor stem cell transplant, treosulfan, fludarabine, and total-body irradiation work in treating patients with blood cancers (hematological malignancies).
- Conditions
- Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Adult Diffuse Large Cell Lymphoma
- Trial name
- NCT04195633
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
Acute Myeloid Leukemia, Acute Undifferentiated Leukemia
Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
This phase I/II trial studies the safety, side effects, and best dose of decitabine in combination with fludarabine, cytarabine, filgrastim, and idarubicin (FLAG-Ida) and total body irradiation (TBI) followed by a donor stem cell…
- Conditions
- Acute Myeloid Leukemia, Acute Undifferentiated Leukemia, Mixed Phenotype Acute Leukemia, Recurrent Acute Myeloid Leukemia
- Trial name
- NCT06928662
- Testing
- Decitabine, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
This is a prospective, multi-center, Phase II study of hematopoietic cell transplantation (HCT) using human leukocyte antigen (HLA)-mismatched unrelated donors (MMUD) for peripheral blood stem cell transplant in adults and bone…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia
- Trial name
- ACCESS (NCT04904588)
- Testing
- Busulfan, Fludarabine, Total-body irradiation
- Where
- 39 sites in United States
- Volunteers
- 300 people
- Sponsor
- Center for International Blood and Marrow Transplant Research
Oral Mucositis, Stomatitis
Amimestrocel Injection for Preventing Severe Oral Mucositis in HSCT Patients
This study aims to see if a single intravenous infusion of a cell therapy called Amimestrocel injection can help prevent severe mouth sores (oral mucositis) in patients receiving a stem cell transplant.
- Conditions
- Oral Mucositis, Stomatitis, Gastrointestinal Mucositis, Hematopoietic Stem Cell Transplantation
- Trial name
- NCT07400328
- Testing
- Amimestrocel injection
- Where
- China
- Volunteers
- 22 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Sickle Cell Disease
Ph I/II Study of Allogeneic SCT for Clinically Aggressive Sickle Cell Disease (SCD)
The investigators propose to determine the engraftment and transplant related morbidity and mortality after a non-myeloablative allogeneic hematopoietic stem cell transplant protocol using immune- suppressive agents and low-dose…
- Trial name
- NCT01499888
- Testing
- Allogeneic Non-Myeloablative Stem Cell Transplantation, Alemtuzumab, Sirolimus
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Illinois Chicago
Leukemia, Multiple Myeloma
Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation
The purpose of this study is to help determine if palifermin and leuprolide acetate can help the immune system recover faster following a stem cell transplant.
- Conditions
- Leukemia, Multiple Myeloma, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma
- Trial name
- NCT01746849
- Testing
- Palifermin, Lupron, peripheral blood stem cell transplantation
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
This phase II trial studies how well giving an umbilical cord blood transplant together with cyclophosphamide, fludarabine, and total-body irradiation (TBI) works in treating patients with hematologic diseases.
- Conditions
- Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm
- Trial name
- NCT06013423
- Testing
- Biospecimen Collection, Bone Marrow Aspirate, Cyclophosphamide
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Fred Hutchinson Cancer Center
Relapsed or Refractory Acute Myeloid Leukemia
A Single-arm, Prospective Study of TBI + BUMEL As a Conditioning Regimen for Salvage HSCT in Patients with R/R AML
Acute myeloid leukemia (AML) is one of the hematologic malignancies, for which patients typically undergo chemotherapy to achieve complete remission.
- Trial name
- NCT06879847
- Testing
- Salvage Allogeneic Hematopoietic Stem Cell Transplantation
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Multiple Myeloma
Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function
Treatment for relapsed/refractory multiple myeloma continues to evolve with the approval of highly effective anti-BCMA CAR T therapies in recent years.
- Trial name
- NCT06623630
- Testing
- Cyclophosphamide, Ciltacabtagene Autoleucel, Total body irradiation
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Washington University School of Medicine
Acute Lymphoblastic Leukemia
A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC)
The current national acute lymphoblastic leukaemia (ALL) trial in adults investigated whether a low (reduced) intensity chemotherapy regimen prior to transplant could improve the outcome of patients with ALL who are over 40 years…
- Trial name
- ALL-RIC (NCT03821610)
- Testing
- Fludarabine, Melphalan, Alemtuzumab
- Where
- 22 sites in United Kingdom
- Volunteers
- 242 people
- Sponsor
- University of Birmingham
Non-Malignant Neoplasm
Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases
This phase I/II trial studies the best dose of total body irradiation with astatine-211 BC8-B10 monoclonal antibody for the treatment of patients with nonmalignant diseases undergoing hematopoietic cell transplant.
- Trial name
- NCT04083183
- Testing
- Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Fred Hutchinson Cancer Center
Systemic Scleroderma
TBI Using IMRT and Cyclophosphamide Prior to Stem Cell Transplant for the Treatment of Severe Systemic Sclerosis
This early phase I trial studies the side effects and feasibility of total body irradiation using intensity modulation radiation therapy (IMRT) when given in combination with cyclophosphamide prior to stem cell transplant to…
- Trial name
- NCT04380831
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Intensity-Modulated Radiation Therapy
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- City of Hope Medical Center
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis
The goal of this clinical trial is to determine the effectiveness of Reduced Dose Post-Transplant Cyclophosphamide (PTCy) in patients with hematologic malignancies after receiving an HLA-Mismatched Unrelated Donor (MMUD) .
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Leukemia, Myelodysplastic Syndromes
- Trial name
- OPTIMIZE (NCT06001385)
- Testing
- Busulfan, Fludarabine, PBSC Hematopoietic Stem Cell Transplantation (HSCT)
- Where
- 32 sites in United States
- Volunteers
- 313 people
- Sponsor
- Center for International Blood and Marrow Transplant Research
Living Donor Kidney Transplantation
TLI, TBI, ATG & Hematopoietic Stem Cell Transplantation and Recipient T Regs Therapy in Living Donor Kidney Transplantation
This study will determine whether a preparatory regimen including total lymphoid irradiation (TLI), total body irradiation (TBI), anti-thymocyte globulin (ATG) and infusion of the donor hematopoietic stem cells when given along…
- Trial name
- NCT03943238
- Testing
- Infusion of Donor Hematopoetic Stem Cells and Recipient Tregs
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Stanford University